Riluzole
- Generic Name
- Riluzole
- Brand Names
- Exservan, Rilutek, Tiglutik, Riluzole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H5F3N2OS
- CAS Number
- 1744-22-5
- Unique Ingredient Identifier
- 7LJ087RS6F
- Background
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
- Indication
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Associated Therapies
- -
Treatment of Refractory Schizophrenia With Riluzole
- Conditions
- Interventions
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 34
- Registration Number
- NCT00375050
- Locations
- 🇺🇸
Yale Department of Psychiatry, New Haven, Connecticut, United States
Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
- Conditions
- Interventions
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- University of Lisbon
- Target Recruit Count
- 63
- Registration Number
- NCT00353665
- Locations
- 🇵🇹
Department of Neurology - Hospital de Santa Maria, Lisbon, Portugal
Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00283309
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
Riluzole in Huntington's Disease
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 537
- Registration Number
- NCT00277602
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 78
- Registration Number
- NCT00251303
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-12-15
- Lead Sponsor
- King's College London
- Target Recruit Count
- 800
- Registration Number
- NCT00211224
- Locations
- 🇬🇧
Institute of Psychiatry, King's College London, London, United Kingdom
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- S. Andrea Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00202397
- Locations
- 🇮🇹
S.Andrea Hospital - University of Rome "La Sapienza", Rome, Italy
Riluzole to Treat Depression in Bipolar Disorder
- First Posted Date
- 2003-02-07
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 19
- Registration Number
- NCT00054704
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Riluzole to Treat Major Depression
- Conditions
- First Posted Date
- 2001-11-09
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 31
- Registration Number
- NCT00026052
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.